Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trialJohann S. de Bono, Ulrik Lassen, Joo Ern Ang et al.|The Lancet Oncology|2019Cited by 228
First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic CancerSarah P. Blagden, Udai Banerji, Aurelius Olmin et al.|Clinical Cancer Research|2014Cited by 47
Geographical variations in the use of cancer treatments are associated with survival of lung cancer patientsHenrik Møller, James Spicer, Victoria H. Coupland et al.|Thorax|2018Cited by 44
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trialJames Spicer, Sophia N. Karagiannis, Bristi Basu et al.|Nature Communications|2023Cited by 35
A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.Aurelius Omlin, Sarah P. Blagden, James Spicer et al.|Journal of Clinical Oncology|2012Cited by 5